Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have evolved from novel therapies for type 2 diabetes mellitus into widely used treatments for obesity and metabolic disease. Their origins can be traced to the Gila monster (Heloderma suspectum), a venomous lizard native to the deserts of the southwestern United States and northwestern Mexico. The discovery of exendin-4, a peptide isolated from the venom of the Gila monster, led to the subsequent development of longer acting GLP-1RAs. Long before its contribution to modern medicine would be recognized, the Gila monster was revered in Navajo culture and folklore. We have examined the historic development of GLP-1 RAs, from the natural history and cultural significance of the Gila monster to the discovery of exendin-4 and the subsequent development of modern therapeutics. We describe the scientific advances that led to the translation of a venom-derived peptide into a major therapeutic class, including the development of exenatide, liraglutide and semaglutide. The history of GLP-1 receptor agonists demonstrates how observations in nature can lead to major therapeutic advances. What began with a view of a venomous desert lizard has evolved into one of the most important therapeutic classes in modern metabolic medicine, with expanding therapeutic applications in dermatology. The Gila monster (Heloderma suspectum) is a venomous lizard native to the deserts of the southwestern United States and northwestern Mexico. Long revered in indigenous cultural traditions, the Gila monster made an unexpected contribution to modern medicine. The discovery of exendin-4, a peptide within its venom, ultimately led to the development of glucagon-like peptide-1 receptor agonists (GLP-1RAs), representing one of the most significant therapeutic advances in modern metabolic medicine. GLP-1RAs are synthetic polypeptides that mimic the actions of the endogenous incretin hormone glucagon-like peptide-1. Initially developed for the treatment of type 2 diabetes mellitus, they have transformed obesity management and are now among the most widely prescribed therapies worldwide. As recognition of obesity has emerged as a major global public health challenge, GLP-1RAs have provided an effective pharmacologic approach to weight management. According to the World Health Organization, more than 1 billion people worldwide have been living with obesity as of 2022 [1]. The success of GLP-1RAs can be traced to the discovery of exendin-4, a peptide isolated from Gila monster venom that shares key biologic properties with human GLP-1 while demonstrating greater resistance to enzymatic degradation. Emerging evidence suggests that GLP-1RAs may influence inflammatory skin disease through a combination of weight reduction, improvements in metabolic health, and modulation of inflammatory and immune pathways [2]. This has generated increasing interest in the potential applications of GLP-1RAs within dermatology. In this review, we have examined the cultural significance and physiologic adaptations of the Gila monster, the discovery of exendin-4 and the subsequent development of GLP-1 RAs from venom-derived peptide to an expanding modern therapeutic class. We have explored how observations from a venomous desert lizard has translated into one of the most important therapeutic advances in metabolic medicine with evolving therapeutic applications in dermatology.
